Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 20, Issue 2, Pages 219-230
Publisher
Informa UK Limited
Online
2018-11-09
DOI
10.1080/14656566.2018.1543407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson’s disease
- (2018) Marina Svetel et al. Expert Opinion on Drug Metabolism & Toxicology
- Dyskinesias and levodopa therapy: why wait?
- (2018) Michele Matarazzo et al. JOURNAL OF NEURAL TRANSMISSION
- Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities
- (2018) Barbara Picconi et al. JOURNAL OF NEURAL TRANSMISSION
- Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson's disease?
- (2018) Keisuke Suzuki et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease
- (2018) Hubert H. Fernandez et al. MOVEMENT DISORDERS
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
- (2018) Susan H. Fox et al. MOVEMENT DISORDERS
- Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease
- (2018) Joaquim J. Ferreira et al. NEUROLOGY
- Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
- (2018) Vibhash Sharma et al. Therapeutics and Clinical Risk Management
- L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey
- (2017) S. Perez-Lloret et al. EUROPEAN JOURNAL OF NEUROLOGY
- Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA
- (2017) Andrew J. Lees et al. Expert Review of Neurotherapeutics
- Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study
- (2017) Roberta Biundo et al. MOVEMENT DISORDERS
- Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)
- (2017) Wolfgang Oertel et al. MOVEMENT DISORDERS
- Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System
- (2017) Amnon C. Sintov et al. PHARMACEUTICAL RESEARCH
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
- (2017) Robert A. Hauser et al. Journal of Parkinsons Disease
- Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA
- (2017) Andrew J. Lees et al. Expert Review of Neurotherapeutics
- Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations
- (2017) Anthony H. V. Schapira et al. JAMA Neurology
- Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease
- (2016) Alessandra Nicoletti et al. JOURNAL OF NEUROLOGY
- Mavoglurant in Parkinson's patients withl-Dopa-induced dyskinesias: Two randomized phase 2 studies
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
- (2016) François Tison et al. MOVEMENT DISORDERS
- Antidyskinetic effect of A2Aand 5HT1A/1Breceptor ligands in two animal models of Parkinson's disease
- (2016) Annalisa Pinna et al. MOVEMENT DISORDERS
- Levodopa therapy for Parkinson disease: Table
- (2016) Peter A. LeWitt et al. NEUROLOGY
- Risk and course of motor complications in a population-based incident Parkinson's disease cohort
- (2016) Anders Bjornestad et al. PARKINSONISM & RELATED DISORDERS
- Memantine and reduced time with dyskinesia in Parkinson′s Disease
- (2015) K. Wictorin et al. ACTA NEUROLOGICA SCANDINAVICA
- Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies
- (2015) Sabeena Sharma et al. BIOMEDICINE & PHARMACOTHERAPY
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study
- (2015) Miho Murata et al. MOVEMENT DISORDERS
- New treatments for levodopa-induced motor complications
- (2015) Olivier Rascol et al. MOVEMENT DISORDERS
- Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
- (2015) Rajesh Pahwa et al. MOVEMENT DISORDERS
- D3dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia
- (2015) Doris E. Payer et al. NEUROLOGY
- Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist
- (2015) Hanna Iderberg et al. NEUROPHARMACOLOGY
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
- (2015) Matthieu F. Bastide et al. PROGRESS IN NEUROBIOLOGY
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease
- (2015) Robert A. Hauser et al. JAMA Neurology
- The acute brain response to levodopa heralds dyskinesias in Parkinson disease
- (2014) Damian M. Herz et al. ANNALS OF NEUROLOGY
- A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias
- (2014) Antonio Cerasa et al. BRAIN
- The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
- (2014) R. Cilia et al. BRAIN
- Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials
- (2014) Yingqun Tao et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
- (2014) Eva Schaeffer et al. CNS DRUGS
- Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
- (2014) Annalisa Pinna CNS DRUGS
- Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease
- (2014) Manuela Pilleri et al. Expert Opinion On Drug Safety
- Emerging drugs for levodopa-induced dyskinesia
- (2014) Amaal Al Dakheel et al. EXPERT OPINION ON EMERGING DRUGS
- Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients
- (2014) Marios Politis et al. JOURNAL OF CLINICAL INVESTIGATION
- Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease
- (2014) María T. Cáceres-Redondo et al. JOURNAL OF NEUROLOGY
- Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial
- (2014) PD MED Collaborative Group LANCET
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
- (2014) Robert A Hauser et al. LANCET NEUROLOGY
- Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease
- (2014) Rupam Borgohain et al. MOVEMENT DISORDERS
- Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis
- (2014) Chuan Zhu et al. NEUROLOGICAL RESEARCH
- Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease
- (2014) J. Y. Hong et al. NEUROLOGY
- Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias
- (2014) Olivier Rascol et al. PARKINSONISM & RELATED DISORDERS
- Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
- (2014) M. Angela Cenci Frontiers in Neurology
- L-DOPA Treatment Selectively Restores Spine Density in Dopamine Receptor D2–Expressing Projection Neurons in Dyskinetic Mice
- (2013) Luz M. Suárez et al. BIOLOGICAL PSYCHIATRY
- Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease
- (2013) Susan H. Fox DRUGS
- Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action
- (2013) Hanna Iderberg et al. EXPERIMENTAL NEUROLOGY
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
- (2013) C Warren Olanow et al. LANCET NEUROLOGY
- Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
- (2013) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
- (2013) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
- (2013) C. Warren Olanow et al. MOVEMENT DISORDERS
- Caffeine consumption and risk of dyskinesia in CALM-PD
- (2013) Anne-Marie A. Wills et al. MOVEMENT DISORDERS
- Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease
- (2013) Maryka Quik et al. MOVEMENT DISORDERS
- Wearing Off, Dyskinesia, and the Use of Continuous Drug Delivery in Parkinson's Disease
- (2013) Peter Jenner NEUROLOGIC CLINICS
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- (2013) F. Ory-Magne et al. NEUROLOGY
- Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients
- (2012) Dag Nyholm et al. AAPS Journal
- Off spells and dyskinesias: Pharmacologic management of motor complications
- (2012) T. S. KHAN CLEVELAND CLINIC JOURNAL OF MEDICINE
- Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
- (2012) Susan Duty CNS DRUGS
- Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
- (2012) J. J. Ferreira et al. EUROPEAN JOURNAL OF NEUROLOGY
- IPX066: a novel carbidopa–levodopa extended-release formulation
- (2012) Robert A Hauser Expert Review of Neurotherapeutics
- Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
- (2012) P. A. LeWitt et al. NEUROLOGY
- Amantadine: The journey from fighting flu to treating Parkinson disease
- (2012) G. Hubsher et al. NEUROLOGY
- Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial
- (2012) O. Rascol et al. PARKINSONISM & RELATED DISORDERS
- Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
- (2011) Imtiaz Ahmed et al. BRAIN
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- (2011) Robert A Hauser et al. LANCET NEUROLOGY
- Increased prefrontal volume in PD with levodopa-induced dyskinesias: A voxel-based morphometry study
- (2011) Antonio Cerasa et al. MOVEMENT DISORDERS
- Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials
- (2011) Cristina Sampaio et al. MOVEMENT DISORDERS
- Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
- (2011) Emmanuelle Pourcher et al. PARKINSONISM & RELATED DISORDERS
- Factors Associated With Motor Fluctuations and Dyskinesia in Parkinson Disease
- (2010) Fabrizio Stocchi et al. CLINICAL NEUROPHARMACOLOGY
- Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial
- (2010) Martin Wolz et al. JOURNAL OF NEURAL TRANSMISSION
- Long-term antidyskinetic efficacy of amantadine in Parkinson's disease
- (2010) Elisabeth Wolf et al. MOVEMENT DISORDERS
- Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease
- (2010) P. Stathis et al. MOVEMENT DISORDERS
- Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
- (2010) Ray L. Watts et al. MOVEMENT DISORDERS
- Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study
- (2010) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias
- (2010) B. Ouattara et al. NEUROSCIENCE
- Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
- (2009) ARCHIVES OF NEUROLOGY
- Levodopa-Induced Dyskinesias in Parkinson Disease Are Independent of the Extent of Striatal Dopaminergic Denervation
- (2009) Gurutz Linazasoro et al. CLINICAL NEUROPHARMACOLOGY
- Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists
- (2009) Vladimir S. Kostić PARKINSONISM & RELATED DISORDERS
- Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
- (2009) H.H. Fernandez et al. PARKINSONISM & RELATED DISORDERS
- The selective α1adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease
- (2009) Kerstin Buck et al. SYNAPSE
- Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
- (2008) Peter A. LeWitt et al. ANNALS OF NEUROLOGY
- Parkinson's disease: Levodopa-induced dyskinesia and signal transduction
- (2008) Emanuela Santini et al. FEBS Journal
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
- (2008) John G. Nutt et al. MOVEMENT DISORDERS
- Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
- (2008) Pedro J. García Ruiz et al. MOVEMENT DISORDERS
- Adenosine and its receptors: Multiple modulatory functions and potential therapeutic targets for neurologic disease
- (2008) E. E. Benarroch NEUROLOGY
- Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
- (2008) R. Katzenschlager et al. NEUROLOGY
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
- (2008) M. Stacy et al. NEUROLOGY
- Priming for l-dopa-induced dyskinesia in Parkinson’s disease: A feature inherent to the treatment or the disease?
- (2008) Agnès Nadjar et al. PROGRESS IN NEUROBIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started